ASCO Endorses Cancer Care Ontario Breast Cancer Guidelines

The American Society of Clinical Oncology has endorsed the Cancer Care Ontario recommendations on the role of patient and disease factors in selecting adjuvant therapy for early-stage breast cancer, according to a special article published online March 21 in the Journal of Clinical Oncology.

IHPI member N. Lynn Henry, M.D., from the University of Michigan Comprehensive Cancer Center in Ann Arbor, and colleagues reviewed the CCO guidelines for methodologic rigor and assessed the content of the recommendations.

"The ASCO panel endorses the recommendations with minor suggested revisions and highlights three areas that warrant further consideration: tumor histology and adjuvant therapy recommendations, risk stratification tools, and proposed Oncotype DX recurrence score thresholds to guide decisions about chemotherapy, and patient factors in decision making," the authors write.